Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinib

Ruxolitinib was an effective salvage therapy for relapsed/refractory secondary hemophagocytic lymphohistiocytosis. Prolonged maintenance with a ruxolitinib taper obviated the need for intensive chemotherapy or allogeneic transplant in secondary HLH.

Shranjeno v:
Bibliografske podrobnosti
izdano v:Blood Adv
Main Authors: Goldsmith, Scott R., Saif Ur Rehman, Sana, Shirai, Cara L., Vij, Kiran, DiPersio, John F.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2019
Teme:
Exceptional Case Report
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6963250/
https://ncbi.nlm.nih.gov/pubmed/31821455
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000898
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki